Nadia Chouaki

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu et al. · Journal of Clinical Oncology · 2013 · 635 citations

Medicine, Oncology, Pharmacotherapy +16

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu et al. · The Lancet Oncology · 2012 · 614 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

Suresh Senan, Anthony Brade, Lu-hua Wang et al. · Journal of Clinical Oncology · 2016 · 437 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis

Jean-Louis Pujol, Sofia Paul, Nadia Chouaki et al. · Journal of Thoracic Oncology · 2007 · 66 citations · Full text

Pharmacy, Oncology, Pharmacology +14

Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngealtype

Ali Hasbini, R. Mahjoubi, Abderrahim Fandi et al. · Annals of Oncology · 1999 · 57 citations · Full text

Medicine, Oncology, Pharmacology +13